Protalix BioTherapeutics (PLX) Amortization of Deferred Charges (2013 - 2023)

Protalix BioTherapeutics' Amortization of Deferred Charges history runs 11 years deep, the most recent figure standing at $59000.0 for Q4 2023.

• In Q4 2023, Amortization of Deferred Charges fell 22.37% year-over-year to $59000.0; the TTM figure through Dec 2023 stood at $267000.0 (down 11.0% YoY), while the FY2023 annual figure was $267000.0, down 11.0% from the prior year.
• Amortization of Deferred Charges for Q4 2023 stood at $59000.0, down from $60000.0 in the prior quarter.
• The five-year high for Amortization of Deferred Charges was $983000.0 in Q2 2021, with the low at $59000.0 in Q4 2023.
• The 5-year median for Amortization of Deferred Charges is $672500.0 (2019), against an average of $485050.0.
• The sharpest annual moves came in 2020 and 2022: Amortization of Deferred Charges grew 16.48% in 2020, then sank 92.78% in 2022.
• Protalix BioTherapeutics' Amortization of Deferred Charges stood at $794000.0 in 2019, then advanced by 16.12% to $922000.0 in 2020, then slumped by 88.72% to $104000.0 in 2021, then dropped by 26.92% to $76000.0 in 2022, then retreated by 22.37% to $59000.0 in 2023.
• Business Quant data shows PLX's Amortization of Deferred Charges at $59000.0 in Q4 2023, $60000.0 in Q3 2023, and $68000.0 in Q2 2023.